STERIS (NYSE:STE) Posts Quarterly Earnings Results, Beats Estimates By $0.17 EPS

STERIS (NYSE:STE) released its earnings results on Wednesday. The medical equipment provider reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.41 by $0.17, Briefing.com reports. STERIS had a return on equity of 13.67% and a net margin of 10.48%. The business had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.41 billion. During the same quarter last year, the business posted $2.30 earnings per share. The business’s quarterly revenue was up 10.8% compared to the same quarter last year. STERIS updated its FY 2025 guidance to 9.050-9.250 EPS and its FY25 guidance to $9.05 to $9.25 EPS.

STERIS Trading Down 1.3 %

NYSE:STE opened at $210.20 on Thursday. The stock has a 50-day simple moving average of $217.16 and a 200-day simple moving average of $215.97. The stock has a market cap of $20.77 billion, a P/E ratio of 36.81 and a beta of 0.81. STERIS has a 1 year low of $185.22 and a 1 year high of $254.00. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.49 and a current ratio of 2.43.

STERIS Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 26th. Stockholders of record on Wednesday, June 12th will be given a dividend of $0.52 per share. The ex-dividend date is Wednesday, June 12th. This represents a $2.08 annualized dividend and a dividend yield of 0.99%. STERIS’s dividend payout ratio is currently 36.43%.

Wall Street Analyst Weigh In

STE has been the topic of a number of research analyst reports. Stephens restated an “overweight” rating and issued a $250.00 target price on shares of STERIS in a research report on Friday, February 9th. TheStreet upgraded STERIS from a “c+” rating to a “b” rating in a research report on Wednesday, February 7th. JMP Securities restated a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a research report on Thursday, February 8th. StockNews.com cut STERIS from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. Finally, KeyCorp started coverage on STERIS in a research note on Tuesday, February 6th. They issued an “overweight” rating and a $253.00 price objective for the company. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $239.60.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.